Bristol-Myers Squibb (BMY)
NYSE: BMY
· Real-Time Price · USD
48.30
0.45 (0.94%)
At close: May 30, 2025, 3:59 PM
48.20
-0.20%
After-hours: May 30, 2025, 05:55 PM EDT
Bristol-Myers Squibb Revenue Breakdown
| Period Ending | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | Dec 31, 2018 | Dec 31, 2017 | Dec 31, 2016 | Dec 31, 2015 | Dec 31, 2014 | Dec 31, 2013 | Dec 31, 2012 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Abecma Revenue | 406M | 472M | 388M | 164M | 1.25B | 166M | 6.44B | 4.87B | 3.34B | 1.86B | 774M | 146M | 2M |
| Abecma Revenue Growth | -13.98% | +21.65% | +136.59% | -86.85% | +651.20% | -97.42% | +32.14% | +45.74% | +79.73% | +140.31% | +430.14% | +7200.00% | n/a |
| Abraxane Revenue | 875M | 1B | 811M | 1.18B | 9.17B | 7.93B | 6.74B | 4.95B | 3.77B | 942M | 6M | 1.44B | 1.18B |
| Abraxane Revenue Growth | -12.85% | +23.80% | -31.33% | -87.12% | +15.63% | +17.73% | +36.12% | +31.11% | +300.64% | +15600.00% | -99.58% | +22.79% | n/a |
| Breyanzi Revenue | 747M | 364M | 182M | 87M | 6.99B | 7.2B | 2.71B | 2.48B | 2.27B | 1.89B | 1.65B | 1.28B | 1.02B |
| Breyanzi Revenue Growth | +105.22% | +100.00% | +109.20% | -98.76% | -2.94% | +165.83% | +9.32% | +9.45% | +20.16% | +14.10% | +29.06% | +25.61% | n/a |
| Camzyos Revenue | 602M | 231M | 24M | 10.76B | 3.16B | 2.98B | 2B | 2B | 1.82B | 1.62B | 1.49B | 960M | 706M |
| Camzyos Revenue Growth | +160.61% | +862.50% | -99.78% | +240.89% | +6.05% | +48.85% | -0.25% | +9.92% | +12.59% | +8.51% | +55.52% | +35.98% | n/a |
| Cobenfy Revenue | 10M | 12.21B | 11.79B | 7.52B | 3.07B | 322M | 1.33B | 1.24B | 1.05B | 1.13B | 1.31B | n/a | n/a |
| Cobenfy Revenue Growth | -99.92% | +3.54% | +56.71% | +145.05% | +853.42% | -75.79% | +6.91% | +18.14% | -6.48% | -13.91% | n/a | n/a | n/a |
| Eliquis Revenue | 13.33B | 9.01B | 8.25B | 3.31B | 274M | 1.3B | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Eliquis Revenue Growth | +48.00% | +9.21% | +149.52% | +1106.57% | -78.91% | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Krazati Revenue | 126M | 627M | 252M | 3.33B | 12.11B | 2.11B | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Krazati Revenue Growth | -79.90% | +148.81% | -92.44% | -72.48% | +473.74% | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Opdivo Revenue | 9.3B | 3.6B | 3.46B | 551M | 2.14B | 1.49B | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Opdivo Revenue Growth | +158.37% | +3.95% | +528.68% | -74.25% | +43.72% | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Opdualag Revenue | 928M | 3.44B | 3.5B | 12.82B | 1.68B | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Opdualag Revenue Growth | -73.03% | -1.60% | -72.72% | +662.25% | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Orencia Revenue | 3.68B | 1.01B | 717M | 2.12B | 12M | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Orencia Revenue Growth | +265.28% | +40.59% | -66.13% | +17541.67% | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Other Growth Brands Revenue | 1.6B | 6.1B | 9.98B | 2.03B | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Other Growth Brands Revenue Growth | -73.68% | -38.90% | +392.50% | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Other Legacy Brands Revenue | 925M | 170M | 8M | 134M | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Other Legacy Brands Revenue Growth | +444.12% | +2025.00% | -94.03% | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Pomalyst/Imnovid Revenue | 3.54B | 1.93B | 2.17B | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Pomalyst/Imnovid Revenue Growth | +83.68% | -10.85% | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Reblozyl Revenue | 1.77B | 2.24B | 2.13B | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Reblozyl Revenue Growth | -20.78% | +5.02% | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Revlimid Revenue | 5.77B | 434M | 250M | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Revlimid Revenue Growth | +1230.18% | +73.60% | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Sotyktu Revenue | 246M | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Sotyktu Revenue Growth | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Sprycel Revenue | 1.29B | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Sprycel Revenue Growth | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Yervoy Revenue | 2.53B | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Yervoy Revenue Growth | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Zeposia Revenue | 566M | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Zeposia Revenue Growth | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Revenue by Geography
| Period Ending | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | Dec 31, 2018 | Dec 31, 2017 | Dec 31, 2016 | Dec 31, 2015 | Dec 31, 2014 | Dec 31, 2013 | Dec 31, 2012 | Dec 31, 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Other Region Revenue | 996M | 699M | 834M | 852M | 631M | 524M | 584M | 553M | 528M | 739M | 1.11B | 842M | 327M | 89M |
| Other Region Revenue Growth | +42.49% | -16.19% | -2.11% | +35.02% | +20.42% | -10.27% | +5.61% | +4.73% | -28.55% | -33.54% | +32.07% | +157.49% | +267.42% | n/a |
| United States Revenue | 34.1B | 31.55B | 31.83B | 29.21B | 26.58B | 15.34B | 12.59B | 11.36B | 10.72B | 8.19B | 7.72B | 8.32B | 10.38B | 13.85B |
| United States Revenue Growth | +8.08% | -0.86% | +8.95% | +9.92% | +73.23% | +21.90% | +10.81% | +5.95% | +30.92% | +6.12% | -7.24% | -19.90% | -25.00% | n/a |
Operating Expense Breakdown
| Period Ending | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | Dec 31, 2018 | Sep 30, 2018 | Jun 30, 2018 | Mar 31, 2018 | Dec 31, 2017 | Sep 30, 2017 | Jun 30, 2017 | Mar 31, 2017 | Dec 31, 2016 | Sep 30, 2016 | Jun 30, 2016 | Mar 31, 2016 | Dec 31, 2015 | Sep 30, 2015 | Jun 30, 2015 | Mar 31, 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selling, General, and Administrative Revenue | 1.58B | 2.14B | 1.98B | 1.92B | 2.37B | 2.07B | 2B | 1.93B | 1.76B | 2.27B | 1.93B | 1.79B | 1.83B | 2.35B | 1.79B | 1.88B | 1.67B | 2.72B | 1.71B | 1.63B | 1.61B | 1.73B | 1.05B | 1.08B | 1.01B | 1.34B | 1.1B | 1.13B | 980M | 1.37B | 1.17B | 1.2B | 1.11B | 1.49B | 1.16B | 1.26B | 1.09B | 1.55B | 1.22B | 1.17B | 1.06B |
| Selling, General, and Administrative Revenue Growth | -25.84% | +7.72% | +3.17% | -18.80% | +14.18% | +3.49% | +3.57% | +9.76% | -22.24% | +17.41% | +8.00% | -2.40% | -22.22% | +31.66% | -4.99% | +12.97% | -38.77% | +59.50% | +4.79% | +1.37% | -7.38% | +64.36% | -1.95% | +6.96% | -24.70% | +21.01% | -2.39% | +15.41% | -28.47% | +17.19% | -2.83% | +8.67% | -25.50% | +27.77% | -7.92% | +15.87% | -29.68% | +26.63% | +4.53% | +10.89% | n/a |
| Research and Development Revenue | 2.26B | 3.22B | 2.37B | 2.29B | 2.69B | 2.48B | 2.24B | 2.26B | 2.32B | 2.51B | 2.42B | 2.32B | 2.26B | 2.52B | 3.25B | 3.27B | 2.23B | 3.75B | 2.5B | 2.52B | 2.37B | 2.1B | 1.38B | 1.33B | 1.35B | 1.38B | 1.28B | 2.44B | 1.25B | 1.92B | 1.54B | 1.66B | 1.29B | 1.4B | 1.14B | 1.27B | 1.14B | 1.92B | 1.13B | 1.86B | 1.02B |
| Research and Development Revenue Growth | -29.93% | +35.68% | +3.44% | -14.84% | +8.76% | +10.53% | -0.71% | -2.71% | -7.53% | +3.80% | +4.18% | +2.70% | -10.25% | -22.55% | -0.61% | +47.01% | -40.67% | +50.06% | -0.91% | +6.32% | +13.11% | +51.74% | +4.07% | -1.70% | -2.10% | +7.81% | -47.43% | +94.80% | -34.93% | +24.50% | -6.99% | +28.80% | -8.00% | +23.02% | -10.11% | +11.44% | -40.71% | +69.26% | -39.01% | +82.68% | n/a |
| Sales and Marketing Revenue | 1.58B | 1.5B | 1.98B | n/a | 2.37B | 1.4B | 2B | n/a | 1.76B | 2.27B | 1.93B | n/a | n/a | 2.35B | 1.79B | n/a | 1.67B | 2.72B | 1.71B | 1.63B | 1.61B | 1.73B | 1.05B | 1.08B | 1.01B | 1.34B | 1.1B | 1.13B | 980M | 1.3B | 1.15B | 1.17B | 1.07B | 1.46B | 1.14B | 1.24B | 1.07B | 1.5B | 1.18B | 1.14B | 1.03B |
| Sales and Marketing Revenue Growth | +5.60% | -24.36% | n/a | -100.00% | +69.07% | -30.10% | n/a | -100.00% | -22.24% | +17.41% | n/a | n/a | -100.00% | +31.66% | n/a | -100.00% | -38.77% | +59.50% | +4.79% | +1.37% | -7.38% | +64.36% | -1.95% | +6.96% | -24.70% | +21.01% | -2.39% | +15.41% | -24.56% | +13.25% | -1.71% | +8.66% | -26.49% | +27.71% | -7.59% | +15.92% | -28.85% | +27.64% | +3.61% | +10.30% | n/a |